PTEN deletion is present in approximately 30–40% of GBM [14, 15], however there is no unanimity regarding the prognostic value of this alteration in diffuse gliomas [16, 17], as well as, regarding TERT promoter mutations [18–20] and EGFR amplification [21–23]. This evidence concerns the gene PTEN and glioblastoma.